FDA ap­proves can­cer ra­di­a­tion drug Aze­dra, send­ing Prog­en­ics stock north

Prog­en­ics of­fi­cial­ly got a thumbs up from the FDA on its can­cer ra­di­a­tion ther­a­py Aze­dra, send­ing the New York com­pa­ny’s stock climb­ing Mon­day af­ter­noon. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER